Suppr超能文献

兴奋剂与单胺氧化酶抑制剂联合使用:用途综述及一种可能的额外适应症

Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication.

作者信息

Feinberg S Shalom

机构信息

Department of Psychiatry, Albert Einstein College of Medicine, Bronx, NY, USA.

出版信息

J Clin Psychiatry. 2004 Nov;65(11):1520-4. doi: 10.4088/jcp.v65n1113.

Abstract

BACKGROUND

Among antidepressant augmentation strategies, the addition of a stimulant to a monoamine oxidase inhibitor (MAOI) has received little attention in the literature in recent years because of the diminished clinical use of the latter and concerns of precipitating a hypertensive crisis or other serious complication. Despite that fact, experienced clinicians continue to use this combination for a variety of indications after other options have failed. This article reviews these reported uses and presents a case suggesting another possible indication.

METHOD

A MEDLINE search was conducted for articles published from 1962 to December 2003 using relevant search terms (psychostimulant, stimulant, amphetamine, dextroamphetamine, pemoline or methylphenidate, atomoxetine, bupropion, monoamine oxidase inhibitor, and selegiline). A manual search was conducted of cross-references and other relevant recent psychiatric sources (2000-2003).

RESULTS

The described uses of the MAOI-stimulant combination have included treatment of refractory depression and the MAOI-related side effects of orthostatic hypotension and daytime sedation. No documented reports were found in the recent literature of hypertensive crises or fatalities occurring when the stimulant was cautiously added to the MAOI. Also presented here is another possible indication for this therapeutic regimen: treatment of attention-deficit/hyperactivity disorder in an adult patient whose major depression had uniquely responded to the MAOI tranylcypromine.

CONCLUSION

As in other fields of medicine, potentially hazardous medication combinations are utilized in psychiatry after cautiously weighing the danger of the treatment against the morbidity and risk of not adequately addressing the illness. Particularly, as the potential arrival of the apparently safer transdermal selegiline may increase the use of MAOIs, we feel this combination deserves additional controlled study.

摘要

背景

在抗抑郁增效策略中,近年来,由于单胺氧化酶抑制剂(MAOI)的临床应用减少以及担心引发高血压危象或其他严重并发症,在文献中很少关注将兴奋剂添加到MAOI中这种做法。尽管如此,在其他选择均告失败后,经验丰富的临床医生仍继续将这种联合用药用于多种适应症。本文回顾了这些已报道的用法,并呈现了一个病例,提示了另一种可能的适应症。

方法

使用相关检索词(精神兴奋剂、兴奋剂、苯丙胺、右旋苯丙胺、匹莫林或哌甲酯、托莫西汀、安非他酮、单胺氧化酶抑制剂和司来吉兰)对1962年至2003年12月发表的文章进行了MEDLINE检索。对手动检索交叉引用和其他近期相关精神病学资料(2000 - 2003年)。

结果

MAOI与兴奋剂联合使用的已描述用途包括治疗难治性抑郁症以及MAOI相关的体位性低血压和日间镇静副作用。在近期文献中未发现有记录的报告表明当谨慎地将兴奋剂添加到MAOI中时会发生高血压危象或死亡。本文还提出了这种治疗方案的另一种可能适应症:治疗一名成年患者的注意力缺陷/多动障碍,该患者的重度抑郁症对MAOI反苯环丙胺有独特反应。

结论

与医学的其他领域一样(在精神病学中),在谨慎权衡治疗的风险与疾病未得到充分治疗的发病率和风险之后,会使用有潜在危险的药物组合。特别是,由于明显更安全的透皮司来吉兰的可能出现可能会增加MAOI的使用,我们认为这种联合用药值得进行更多对照研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验